| Attributes | Values |
|---|
| rdf:type
| |
| rdfs:seeAlso
| |
| Description
| - Background When applying the PET Response Criteria in Solid Tumors protocol, a threshold value based on standardized uptake value corrected to lean body mass (SUL) in liver parenchyma, or in the blood pool, is used: to metabolically specify a measurable lesion; to calculate metabolic tumor volume (mTV) and its product total lesion glycolysis (TLG); and as a limit for response measurement. The problem with using changes in glucose metabolism as a marker for response to therapy is its reproducibility on test-retest examinations. Therefore, before the evaluation of tumor treatment response, we verified our diagnostic protocol for homogeneity using the PET Response Criteria in Solid Tumors quality parameters. In addition, we analyzed the effect of the time span between examinations on the average value of SUL (SULMEAN) in liver parenchyma at three different points: first at baseline (BL), after the first course of chemotherapy (ChT1), and finally after finishing therapy (ChT3). We also analyzed the influence of SULMEAN variation on mTV and TLG. Methods Eighty-four patients with esophageal cancer were prospectively examined at BL using 2-deoxy-2-[F-18]fluoro-D-glucose (F-18-FDG)-PET/CT; 53 of 84 patients were examined after ChT1, 47 of 84 after ChT3, and 41 of 84 underwent all three examinations. Coefficient of variance (CV) and relative differences (RDw) were assessed for test-retest liver SUL values. The influence of liver SULMEAN to mTV and TLG was modeled on BL examinations by artificial changes in liver SULMEAN by +/- 20%.
- Background When applying the PET Response Criteria in Solid Tumors protocol, a threshold value based on standardized uptake value corrected to lean body mass (SUL) in liver parenchyma, or in the blood pool, is used: to metabolically specify a measurable lesion; to calculate metabolic tumor volume (mTV) and its product total lesion glycolysis (TLG); and as a limit for response measurement. The problem with using changes in glucose metabolism as a marker for response to therapy is its reproducibility on test-retest examinations. Therefore, before the evaluation of tumor treatment response, we verified our diagnostic protocol for homogeneity using the PET Response Criteria in Solid Tumors quality parameters. In addition, we analyzed the effect of the time span between examinations on the average value of SUL (SULMEAN) in liver parenchyma at three different points: first at baseline (BL), after the first course of chemotherapy (ChT1), and finally after finishing therapy (ChT3). We also analyzed the influence of SULMEAN variation on mTV and TLG. Methods Eighty-four patients with esophageal cancer were prospectively examined at BL using 2-deoxy-2-[F-18]fluoro-D-glucose (F-18-FDG)-PET/CT; 53 of 84 patients were examined after ChT1, 47 of 84 after ChT3, and 41 of 84 underwent all three examinations. Coefficient of variance (CV) and relative differences (RDw) were assessed for test-retest liver SUL values. The influence of liver SULMEAN to mTV and TLG was modeled on BL examinations by artificial changes in liver SULMEAN by +/- 20%. (en)
|
| Title
| - The analysis of factors affecting the threshold on repeated F-18-FDG-PET/CT investigations measured by the PERCIST protocol in patients with esophageal carcinoma
- The analysis of factors affecting the threshold on repeated F-18-FDG-PET/CT investigations measured by the PERCIST protocol in patients with esophageal carcinoma (en)
|
| skos:prefLabel
| - The analysis of factors affecting the threshold on repeated F-18-FDG-PET/CT investigations measured by the PERCIST protocol in patients with esophageal carcinoma
- The analysis of factors affecting the threshold on repeated F-18-FDG-PET/CT investigations measured by the PERCIST protocol in patients with esophageal carcinoma (en)
|
| skos:notation
| - RIV/00064203:_____/12:8120!RIV13-MZ0-00064203
|
| http://linked.open...avai/predkladatel
| |
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| |
| http://linked.open...iv/cisloPeriodika
| |
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| |
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/00064203:_____/12:8120
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| - esophageal carcinoma; 2-deoxy-2-[F-18]fluoro-D-glucose; neoadjuvant chemotherapy; positron emission tomography Response Criteria in Solid Tumors; positron emission tomography/computed tomography; reproducibility; threshold; positron-emission-tomography; whole-body pet; esophagogastric junction; neoadjuvant therapy; malignant-tumors; uptake values; cancer; reproducibility; chemotherapy; trials (en)
|
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...odStatuVydavatele
| - US - Spojené státy americké
|
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...i/riv/nazevZdroje
| - Nuclear Medicine Communications
|
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...vavai/riv/projekt
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...v/svazekPeriodika
| |
| http://linked.open...iv/tvurceVysledku
| - Haruštiak, Tomáš
- Zemanová, M.
- Belohlavek, O.
- Fencl, P.
|
| http://linked.open...ain/vavai/riv/wos
| |
| issn
| |
| number of pages
| |
| is http://linked.open...avai/riv/vysledek
of | |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)